Title: 2016 ACVIM Forum Research Abstract Program Document date: 2016_5_31
ID: 2y1y8jpx_159
Snippet: Conclusion: The combination of doxorubicin 25 mg/m2 IV q21 days and toceranib 2.75 mg/kg PO EOD was well tolerated. Efficacy and longer term toxicity of this combination should be further investigated in phase II/III trials. In people, changes in the cytokine environment have been linked to the development of lymphoma, and multiple circulating cytokines have been shown to be relevant biomarkers for response to chemotherapy and prognosis. Therefor.....
Document: Conclusion: The combination of doxorubicin 25 mg/m2 IV q21 days and toceranib 2.75 mg/kg PO EOD was well tolerated. Efficacy and longer term toxicity of this combination should be further investigated in phase II/III trials. In people, changes in the cytokine environment have been linked to the development of lymphoma, and multiple circulating cytokines have been shown to be relevant biomarkers for response to chemotherapy and prognosis. Therefore, the purpose of this study was to measure the serum levels of 13 cytokines in dogs with multicentric lymphoma and compare them to a population of healthy dogs. It was hypothesized there would be a significant difference in cytokine levels between dogs with lymphoma and healthy dogs, and between dogs with B cell and T cell lymphoma.
Search related documents:
Co phrase search for related documents- cell lymphoma and lymphoma development: 1, 2, 3, 4, 5, 6, 7, 8, 9
- cell lymphoma and prognosis chemotherapy: 1
- cell lymphoma and serum level: 1, 2, 3
- cell lymphoma and significant difference: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- cell lymphoma and study purpose: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
Co phrase search for related documents, hyperlinks ordered by date